secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2025-08-20T23:59:59+00:00
Accession:  0001104659-25-080473
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute appoints Sunil Karnawat as CCO; grants 275K inducement options
-----------------------------------------------------------------------

- Sunil Karnawat appointed Chief Commercial Officer effective Aug 18, 2025; brings 25+ years experience including four ultra-rare disease launches at Ultragenyx.
- Employment agreement: base salary $475K, annual target bonus 40%, signing bonus $65K, plus 270K stock options and 25K RSUs vesting over time.
- Inducement grant of 275K stock options at $6.55/share (closing price Aug 18); vesting: 25% on first anniversary, then 36 monthly installments, accelerated upon change of control.
- Karnawat will lead launch strategy and global market readiness for ersodetug, a Phase 3 therapy for congenital and tumor hyperinsulinism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925080473/0001104659-25-080473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925080473/tm2523938d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-080473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer